Flexner's work is focused on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections. He has published over 250 scientific manuscripts,reviews,and book chapters on the use of drugs for the treatment and prevention of HIV and other infectious diseases,this includes early studies of HIV protease inhibitors,and the use of accelerator mass spectrometry to determine drug disposition in humans.[2] He has also authored several books and textbooks,including Protease Inhibitors in AIDS Therapy,Integrative Pharmacology,Antiretroviral Drug Interactions:A Practical Approach,and 2012 DDI:HIV Drug Interaction Guide.
Flexner served as President of the American Federation for Medical Research (AFMR),and the AFMR Foundation.
Education
Flexner received a B.S. degree in biology from Stanford University in 1978,and his M.D. degree from the Johns Hopkins School of Medicine in 1982. He then completed his internship and residency at Stanford University Hospital in 1985,and a laboratory fellowship with virologist Bernard Moss in the Laboratory of Viral Diseases at the National Institute of Allergy and Infectious Diseases (NIAID) in 1988. In the following year,he served as a Clinical Fellow in Infectious Diseases and Clinical Pharmacology at the Johns Hopkins University School of Medicine.[3]
Career
Following his clinical fellowship,Flexner held appointments as an Assistant Professor of Medicine and Assistant Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine from 1989 until 1996. Along with these appointments,he also held a concurrent appointment as Assistant Professor of International Health at the Johns Hopkins University School of Hygiene and Public Health. In 1996,he was appointed as Associate Professor of Medicine,and Associate Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine,and as Associate Professor of International Health at the Johns Hopkins University Bloomberg School of Public Health. In 2005,he was promoted to the position of Professor of Medicine and Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine,and Professor of International Health at the Johns Hopkins University Bloomberg School of Public Health.[1]
Research
Flexner's research currently focuses on the use of long-acting and extended-release drugs and formulations for the treatment and prevention of HIV and other infectious diseases,including tuberculosis and viral hepatitis.[4] He participated in the discovery and clinical development of several new molecules and formulations for immediate-release and long-acting parenteral administration. He founded and directs the Long Acting/Extended Release Antiretroviral Research Resource Program (LEAP),[5]
In his studies regarding treatment of HIV,Flexner was an early advocate of use of ritonavir to enhance the pharmacokinetics of other drugs. He was also an early proponent of using the combination of the integrase inhibitor,cabotegravir,and the non-nucleoside reverse transcriptase inhibitor,rilpivirine,in a long-acting injectable form as an antiretroviral treatment option for people with HIV.[6] As co-founder of the CADO Conferences,he has promoted the optimization of dose and formulation of antiretroviral drugs for more cost-efficient delivery in resource-limited settings.[7] He also introduced drug development strategies for salvage therapy,and discussed the conflicts and solutions regarding this.[8] In 2010,he studied age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. Results of this study highlighted the potential importance of the pharmacokinetics and tolerability of antiretroviral drugs as the HIV-infected population ages;older individuals comprise an increasing proportion of people living with HIV and AIDS.[9]
Flexner examined human immunodeficiency virus type-1 tropism by conducting a comparative analysis between tropism assays using replication-competent virus and plasma-derived pseudotyped virions. He demonstrated the impact of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers,and found that AMD070 concentrations increased with concomitant ritonavir dosing.[10]
Personal life
Flexner was born in 1956. He is the great-great nephew of the American educator Abraham Flexner,and microbiologist Simon Flexner. He is also a cousin of Pulitzer Prize-winning historian James Thomas Flexner.
Awards and honors
1990 - Clinical Investigator Award,National Institute of Allergy and Infectious Diseases,NIH
1994 - Leon I. Goldberg Young Investigator Award,American Society for Clinical Pharmacology and Therapeutics
1995 - Pfizer Visiting Professor of Medicine and Clinical Pharmacology,Stanford University School of Medicine,Stanford,California.
2004 - M. Glenn Koeing Lecturer,Vanderbilt University School of Medicine
2006 - Joseph E. Murray Lecturer,American Association of Plastic Surgeons
2012 - Honorary Fellow Award,American College of Clinical Pharmacology
Bibliography
Books
Protease Inhibitors in AIDS Therapy (2001) ISBN 9780824704612
HIV Drug Interaction Guide DDI 2012:The Companion Guide to Medical Management of HIV Infection (2012) ISBN 9780983711179
Bakshi, R. P.; Hamzeh, F.; Frank, I.; Eron, J. J. Jr; Bosch, R. J.; Rosenkranz, S. L.; Cramer, Y. S.; Ussery, M.; Flexner, C. (2007). "Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients". AIDS Research and Human Retroviruses. 23 (11): 1360–1365.
Crawford, K. W.; Li, C.; Keung, A.; Su, Z.; Hughes, M. D.; Greaves, W.; Kuritzkes, D.; Gulick, R.; Flexner, C. (2010). "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)". Journal of Acquired Immune Deficiency Syndromes. 53 (5): 598–605.
Rajoli, R.; Flexner, C.; Chiong, J.; Owen, A.; Donnelly, R. F.; Larrañeta, E.; Siccardi, M. (2019). "Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK". European Journal of Pharmaceutics and Biopharmaceutics. 144: 101–109.
↑ Wang, L. Z.; Lee, L. S.; Thuya, W. L.; Soon, G. H.; Kong, L. R.; Nye, P. L.; Lee, E. J.; Flexner, C.; Goh, B. C. (2011). "Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method". Journal of Mass Spectrometry. 46 (2): 202–208. Bibcode:2011JMSp...46..202W. doi:10.1002/jms.1874. PMID21259392.
↑ Flexner, C.; Thomas, D. L.; Swindells, S. (2019). "Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis". Current Opinion in HIV and AIDS. 14 (1): 13–20. doi:10.1097/COH.0000000000000510. PMID30394948. S2CID53216335.
↑ De Gruttola, V.; Flexner, C.; Schapiro, J.; Hughes, M.; Van Der Laan, M.; Kuritzkes, D. R. (2006). "Drug development strategies for salvage therapy: conflicts and solutions". AIDS Research and Human Retroviruses. 22 (11): 1106–1109. doi:10.1089/aid.2006.22.1106. PMID17147496.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
